Research Topics
| Joth JacobsonSummaryAffiliation: Fred Hutchinson Cancer Research Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experienceJoth L Jacobson
Southwest Oncology Group Statistical Center, Seattle, WA 98101 1468, USA
Br J Haematol 122:441-50. 2003..Additional evaluation in other MM patient populations is needed to confirm results...- MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplantsJoth Jacobson
Cancer Research and Biostatistics, Seattle, WA 98101 1468, USA
Br J Haematol 122:430-40. 2003.... - Partitioning and peeling for constructing prognostic groupsMichael LeBlanc
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, MP-557, Seattle, WA 98109-1024, USA
Stat Methods Med Res 11:247-74. 2002..The peeling methods are relatively new and are developed in detail. Simulations and examples for describing groups of patients with poor outcomes using data from a clinical trial for patients with multiple myeloma are presented... - Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trialsBrian G M Durie
Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
J Clin Oncol 22:1857-63. 2004..The purpose was to clarify the predictive value of specific levels of myeloma-associated monoclonal protein reduction and time to first progression using mature data sets... - Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy IIJohn Shaughnessy
Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 120:44-52. 2003..02 and 0.1 respectively) and should be part of the initial work-up of patients with MM... - Treatment of multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 103:20-32. 2004..Fundamental and clinical research should, therefore, focus on the molecular and biologic mechanisms of treatment failure in the high-risk subgroup... - Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioningChoon Kee Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
Exp Hematol 31:73-80. 2003..The aim of this study was to identify prognostic factors for outcome of high-risk patients with multiple myeloma after allogeneic transplantation prepared by reduced intensity conditioning (RIC)... - Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survivalKai-Da Wu
Laboratory of Developmental Hematopoiesis, Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Blood 101:4982-9. 2003..004). The 2-year survival rate for patients with TA levels lower than 25% was 81%, and it was 52% in those with higher TA levels (P <.0001)... - DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myelomaChoon Kee Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Slot 776, 4301 West Markham, Little Rock, AR 72205, USA
J Clin Oncol 21:2732-9. 2003..To improve outcome in previously treated patients (at least two cycles of standard therapy) with multiple myeloma, thalidomide was combined with cytotoxic chemotherapy as induction therapy... - Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survivalMaurizio Zangari
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Clin Lymphoma 4:32-5. 2003..002), and creatinine level > or = 2 mg/dL (P < 0.001). However, the development of DVT did not adversely affect survival when examined as a time-dependent variable and adjusted for standard risk features (hazard ratio, 0.8; P = 0.162)... - Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionJohn Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 101:3849-56. 2003.... - Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group studyCary A Presant
Los Angeles Oncologic Institute, St Vincent Medical Center, CA, USA
Invest New Drugs 20:369-76. 2002..The first 19F-MRS was following 5-FU 600 mg/m2 alone, and the second 19F-MRS was following by leucovorin 500 mg/m2 and then 5-FU 600 mg/m2... - Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulationMaurizio Zangari
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
Br J Haematol 126:715-21. 2004..The rate of DVT recurrence observed in our study upon thalidomide resumption was sufficiently low to allow its continuation in patients who may benefit from this therapeutic intervention...